In Brief: Ela Medical
This article was originally published in The Gray Sheet
Ela Medical: Montrouge, France-based subsidiary of Synthelabo's Biomedical division commences European roll-out of ventricular models of its Stelid family of steroid-eluding pacing leads. The devices incorporate a steroid collar technology that allows for release during the initial days after implantation of the anti-inflammatory drug dexamethasone, and a micro porous carbon electrode. Atrial models of the Stelid devices are undergoing clinical evaluation and are slated for European launch by the end of the year. Separately, Ela reports the European introduction of its Defender II 75 cc dual-chamber defibrillator. The device features the company's Parad algorithm, which allows for collection of both atrial and ventricular data...
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.